Greywolf Reports Durable Responses with First-in-Class ERAP1 Inhibitor
OXFORD, UK, May 22, 2026 Greywolf Therapeutics announced encouraging clinical results from the Phase 1b portion of its ongoing...
MSS CRC
Advertisement
GSK Partners With SBP Group to Expand Hepatitis B Treatment
LONDON, UK – May 11, 2026 GSK plc announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) through...
Innovent Secures Third NMPA Breakthrough Status for IBI363
SAN FRANCISCO and SUZHOU, China, May 10, 2026 Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA)...
Adagene & Incyte Drive New MSS CRC Immunotherapy Study
San Diego, USA & Suzhou, China, April 2, 2026 Breakthrough Collaboration in Immuno-Oncology In a significant step forward for...
Advertisement
